RedHill Biopharma announced positive results on December 10, 2024, from studies confirming the effectiveness of opaganib for treating gastrointestinal acute radiation syndrome (GI-ARS) as part of U.S. government collaborations. Discussions about advancing its development under the FDA’s Animal Rule are ongoing.